Anonymized survey response dataset for: "Multidisciplinary Exploratory Survey: Initial Insights into Biologic Drug Handling and Regulatory Perspectives Among Healthcare Professionals"

DOI: https://doi.org/10.57804/kvv4-wp13

Survey Questions, response type and choices

#	Question	Response type	Options
1	Name / Title (e.g. Dr, PharmD, MSc, Prof)	Open response	- (was later removed)/Notice from authors.
2	Education level /degree type /years practicing	Open response	-
3	Workplace Type	Multiple choice	Hospital, Pharmacy, University, Industry, Other:____
4	Country of Workplace	Open response	-
5	Based on your education and experience, which geographical region do you consider to have the most regulatory expertise?	Multiple choice	Africa, Asia, Central America, Europe, Middle East, North America, Pacific, South America
6	Please provide your role (if you play multiple role, please fill out a survey for each)	Multiple choice	HCP (doctors), HCP (nurse) - who is preparing and administering the biologics, HCP (pharmacist) - Clinical (Does not compound drug), HCP (pharmacist) - Compounding Drugs, Drug developers (Pharmaceutical companies), Academic/educators (e.g. University professor, instructor, academic research institution), Regulators (or enforcement / management of regulations at site), Patient and Caregivers who help administer the medicine but not HCP.

7	Rank from 1 to 8, where do you get information regarding the Biologics that you use and handle (1: highest - 8: lowest) No duplication choice	Multiple choice	HCP professionals (doctors and nurses), HCP professionals (pharmacists), Professional educators (nurses, nurse educators), National/internationals Pharmacy/National Drug Registry (Tressel/SMPC), Organizational informational database, Other patients and patients/caregiver groups (e.g. patient forum), Drug sponsor company, Public literature (Pubmed and/or Google)
8	Check up to 3 boxes where having access to information regarding the biologics you use and/or handle would be most important to you.	Multiple choice	Safety information, Drug Preparation (both in the clinic and at home), Drug Administration (both in the clinic and at home), Drug transport/storage, Other:_____
9	Based on your professional experience, which regulations govern the preparation of biological drugs and their admixture. (Select all that is relevant)	Multiple choice	EU laws (EU commissions/councils),National laws, Local laws (State or region specific), Professional Boards (Pharmacy board of your country), Facility/Site Rules (Hospital rules), US Pharmacopoeia (USP), World Health Organization guidelines (WHO), Other:_____
10	What are the pharmacy board and regulations specific to your country?	Open response	-
11	How often are you there "conflicts or inconsistency" between pharmacy board regulations and your country specific rules to EU overall	Multiple choice	Often >75%, Sometimes ~50%, Rarely (<10%>)

	guidance....often (>75%), sometimes (~50%) and rarely (<10%)		
12	Questions for the pharmacists: there are united EMA guidance for certain handling procedures. E.g. Council of Europe adopted Resolution CM/Res(2016)2 on good reconstitution practices in healthcare establishments for medicinal products for parenteral use. Do you feel more of these guidance would be helpful?	Multiple choice	Yes, more guidance so we can align and potentially reduce patient risks in certain compounding/drug handling practices; No, there are enough guidelines and procedures from my facility, national and local information as well as my professional training; Maybe, some more clarity and guidelines would help my day to day work
13	How are USP (US-based) guidance taken into account, counterpart to EU?	Open response	-
14	Based on your professional experience, which regulations govern storage and transport of biological drugs and their admixture? (Select all that is relevant)	Multiple choice	EU laws (EU commissions/councils), National laws, Local laws (State or region specific), Professional Boards (Pharmacy board of your country), Facility/Site Rules (Hospital rules), US Pharmacopoeia (USP), World Health Organization guidelines (WHO), Other:_____
15	If you work as a pharmacist, who are the responsible people for compliance for drug	Multiple choice	Myself (Pharmacist), Pharmacy Manager, Facility Compliance Manager, Regulatory Person, Drug Sponsor, Other:_____

	preparation and administration at your facilities.		
16	There are many considerations on the expiry date of the compounded solution/admixture (diluted into syringe, or a diluted IV bag). Considerations can be time of puncture of drug vial, biochemical stability or microbial stability. However, the goal is to avoid the use of expired material. In your pharmacy practices, please rank what you are using to make that decision (1: highest priority and 5 lowest priority) No duplication	Multiple choice	Recommendations from local/national pharmaceutical board for that type of products, Biochemical/Physiochemical data provided by database e.g. Tressel/SmPC, Beyond use dates provided by drug developers in their instructions (can include time of pucture of drug vial, biochemical stability), Beyond use dates provided by drug developers in their instructions (microbial stability.), EU guidelines (e.g. EU labelling, reconstitution guide) or other USP guidelines (e.g. 797 Sterile Compounding)
17	Thank you for participating in our survey. The goal is for Project RealHope to use this data to publish our guidance to drive safe delivery of biologics to professionals and patients. If you need additional clarification, we would love to hear from you below.	Open response	-